Boston Scientific Bemoans ICD Market Slide, Cements Cardiovascular Focus
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific may have to adjust revenue projections for its newly acquired Guidant unit due to slowdowns in the cardiac rhythm management market
You may also be interested in...
Guidant’s Last Quarter On Its Own A Downer, But ICD Business Is Rebounding
Guidant's belatedly released first quarter sales were down 6% compared to the same period last year, but the firm's results signal a recovery
Risks Downplayed As Boston Scientific Nears Guidant Acquisition
Boston Scientific claims it can handle the debt it will incur from its approximately $28 bil. acquisition of Guidant and that it has the history to prove it
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.